Clinical Trial Detail

NCT ID NCT01252251
Title RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals
Indications

ocular melanoma

Therapies

Everolimus + Pasireotide

Age Groups: adult

No variant requirements are available.